💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Vorinostat

CHEMBL98 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
264.3 g/mol
LogP
1.9
Phase
4

This histone deacetylase (HDAC) inhibitor is used to treat cutaneous T-cell lymphoma (CTCL), a type of cancer affecting the skin, in patients whose disease has progressed or returned during or after two prior treatments. It works by blocking enzymes that regulate gene expression in cancer cells, promoting their death. Common side effects include fatigue, nausea, and blood clots, and patients need regular monitoring of blood counts and electrolytes.

الوزن الجزيئي

264,3200 g/mol

LogP

1,90

TPSA

78,40 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Melanoma Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Rheumatoid Arthritis Epilepsy Schizophrenia Lymphoma Breast Cancer HIV/AIDS Heart Failure Prostate Cancer Colorectal Cancer Leukemia

آلية العمل

Provides essential ions for maintaining fluid balance, nerve conduction, muscle contraction, and acid-base homeostasis. Supplementation corrects electrolyte imbalances.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Provides essential ions for maintaining fluid balance, nerve conduction, muscle contraction, and acid-base homeostasis. Supplementation corrects electrolyte imbalances.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C(CCCCCCC(=O)Nc1ccccc1)NO

                

                

                
                

                    
InChI

                    
InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)

                

                

                

                    
                    

                        
Molecular Formula

                        
C14H20N2O3

                    

                    
                    

                        
HBD / HBA

                        
3 / 3

                    

                    
                    

                        
الروابط القابلة للدوران

                        
8

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
19

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
This histone deacetylase (HDAC) inhibitor is used to treat cutaneous T-cell lymphoma (CTCL), a type of cancer affecting the skin, in patients whose disease has progressed or returned during or after two prior treatments. It works by blocking enzymes that regulate gene expression in cancer cells, promoting their death. Common side effects include fatigue, nausea, and blood clots, and patients need regular monitoring of blood counts and electrolytes.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Provides essential ions for maintaining fluid balance, nerve conduction, muscle contraction, and acid-base homeostasis. Supplementation corrects electrolyte imbalances.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Vorinostat is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL98.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5311.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.